CAMP

Camp4 Therapeutics Corporation (CAMP) | Rumor.io

Camp4 Therapeutics

CAMP

Attention (50-day avg)0%

Attention rank (50-day avg)#4,619

Bullish sentiment (50-day avg)100%

Price to earnings ratio-1.45

Market capitalization241.6M

Earnings per share-2.31

Dividend yield (TTM)—

Revenue (annual)3.5M

Net income (annual)-80.4M

Social

What share of all stock conversation is about CAMP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 10

CAMP4 Therapeutics Corporation (CAMP) surged 49.4% to $6.28 due to upcoming investor conferences and certification process completion.
The company's upcoming investor conferences are drawing significant attention, and the certification process is now complete, supporting the stock's momentum.
The stock is considered a high-risk, high-reward biotech play, with accelerating profit growth and potential for further gains.

Generated by AI

Sentiment

Of the messages about CAMP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.04% +5.42
Bearish	—	—	0% 0	7.96% -5.42

Bullish· Mar 10

CAMP4 Therapeutics Corporation's stock surges to $6.28, up 49.40%, driven by the company's certification process completion and upcoming investor conferences.
The company's participation in investor conferences signals strategic outreach and supports the stock's high-risk, high-reward momentum play.
CAMP4's profit growth is accelerating rapidly, with the company set for upcoming investor conferences that are drawing significant attention and supporting the stock's surge.

Bearish· Sep 10

$CAMP's price has been heavily influenced by a large short position, which may be causing the stock to tank.
The company's recent private placement has led to significant dilution, which could further impact the stock's value.
The stock's price action has been characterized by a series of small gains followed by larger losses, suggesting a lack of stability and a high risk of further decline.

Generated by AI

Topics

Of the messages about CAMP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	25.41%
Earnings	—	—	0%	57.57%
Analysts	—	—	0%	4.32%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	12.7%

Earnings· Sep 26

CalAmp's Q3 earnings per share is expected to be between $0.11 and $0.17, lower than consensus estimates.
The company's Q2 revenue of $93.23M beat expectations by $1.73M, with Q2 non-GAAP EPS of $0.14 beating by $0.02.
CalAmp's Q2 revenue grew sequentially despite a year-over-year decline, with revenues falling 2.9% from the prior year but increasing 5% from the previous quarter.

Announcements· Dec 18

CAMP4 Therapeutics Corporation ($CAMP) has entered a strategic collaboration with GSK to advance RNA-based therapeutic discoveries, with an upfront payment of $17.5 million and potential milestone payments of up to $440 million.
The collaboration will focus on developing antisense oligonucleotides for neuro and kidney diseases, with CAMP4 eligible to receive up to $440 million in development and commercial milestone payments.
CAMP4 has also announced the pricing of a $30.0 million underwritten offering of common stock, providing additional funding for the company's RNA-based therapeutic research and development efforts.

Generated by AI

Community

Of the messages about CAMP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	6.19%
Newcomers	—	—	100%	93.81%

Regulars· Oct 6

CalAmp's Q2 revenue fell 15% to $61.7M, missing consensus estimates of $70.4M, and the company's shares slid 8.8% as a result.
Analyst Scott Searle of ROTHMKM downgraded CalAmp's price target from $6 to $5, citing a decrease in potential upside.
CalAmp's Q2 earnings were break-even, with the company's shares down about 90% this year.

Newcomers· Mar 10

$CAMP surges 49.40% on certification process completion, with upcoming investor conferences drawing significant attention.
The company's upcoming investor conferences signal strategic outreach, with news supporting visibility but the magnitude of the move suggesting deeper positioning.
Operating leverage expansion and key levels being tested are catalysts for the move, with investor conference participation supporting the news, but caution is required due to high volatility.

Generated by AI

CAMP4 Therapeutics (NASDAQ:CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028. The company’s analyst event focused on CMP-002, an antisense oligon

1d agoYahoo Finance

CAMP4 receives UK authorization for SYNGAP1 trial of CMP-002

20d agoInvesting.com

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Company anticipates initiation of the clinical trial in 4Q 2026 WATERTOWN, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics design

20d agoYahoo Finance

Camp4 Therapeutics at Cantor conference: pushing first SYNGAP1 trial

20d agoInvesting.com

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4’s executive leadersh

21d agoYahoo Finance Singapore

Also Discussed

Investors talking about CAMP also mention

#	Name	Attention
1	SWIR - Sierra Wireless, Inc.	——
2	Barrett Business Services, Inc.BBSI	0%0
3	Apogee Enterprises IncAPOG	0%0
4	Sol-Gel Technologies Ltd.SLGL	0%0
5	Leverage Shares 2x Long CRML Daily ETFCRMU	0%0
6	ATHN - Athena Technology Acquisition Corp.	——
7	AKYA - Akoya Biosciences, Inc.	——
8	dLocal LimitedDLO	0%new
9	JFBR - Jeffs' Brands Ltd	——
10	LanzaTech Global Inc. Common StockLNZA	0%new

Camp4 Therapeutics Corporation

Healthcare
Biotechnology

Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics designed to increase gene expression and restore healthy protein levels. The company applies its ASO-based approach to address the underlying causes of genetic diseases by targeting regulatory RNA and aiming for precise control of protein production. Its work centers on disease areas where insufficient protein activity plays a key role, including disorders affecting the liver and central nervous system. Camp4 Therapeutics Corporation’s current pipeline includes product candidates for urea cycle disorders and SYNGAP1-related disorders, reflecting its focus on rare and genetically driven conditions. Based in Cambridge, Massachusetts, the company operates within the biotechnology sector and contributes to the broader effort to create targeted treatments for inherited diseases through RNA modulation.

Website

Location

One Kendall Square

Cambridge, MA, 02139

United States

Social

What share of all stock conversation is about CAMP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 10

CAMP4 Therapeutics Corporation (CAMP) surged 49.4% to $6.28 due to upcoming investor conferences and certification process completion.
The company's upcoming investor conferences are drawing significant attention, and the certification process is now complete, supporting the stock's momentum.
The stock is considered a high-risk, high-reward biotech play, with accelerating profit growth and potential for further gains.

Generated by AI

Sentiment

Of the messages about CAMP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.04% +5.42
Bearish	—	—	0% 0	7.96% -5.42

Bullish· Mar 10

CAMP4 Therapeutics Corporation's stock surges to $6.28, up 49.40%, driven by the company's certification process completion and upcoming investor conferences.
The company's participation in investor conferences signals strategic outreach and supports the stock's high-risk, high-reward momentum play.
CAMP4's profit growth is accelerating rapidly, with the company set for upcoming investor conferences that are drawing significant attention and supporting the stock's surge.

Bearish· Sep 10

$CAMP's price has been heavily influenced by a large short position, which may be causing the stock to tank.
The company's recent private placement has led to significant dilution, which could further impact the stock's value.
The stock's price action has been characterized by a series of small gains followed by larger losses, suggesting a lack of stability and a high risk of further decline.

Generated by AI

Topics

Of the messages about CAMP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	25.41%
Earnings	—	—	0%	57.57%
Analysts	—	—	0%	4.32%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	12.7%

Earnings· Sep 26

CalAmp's Q3 earnings per share is expected to be between $0.11 and $0.17, lower than consensus estimates.
The company's Q2 revenue of $93.23M beat expectations by $1.73M, with Q2 non-GAAP EPS of $0.14 beating by $0.02.
CalAmp's Q2 revenue grew sequentially despite a year-over-year decline, with revenues falling 2.9% from the prior year but increasing 5% from the previous quarter.

Announcements· Dec 18

CAMP4 Therapeutics Corporation ($CAMP) has entered a strategic collaboration with GSK to advance RNA-based therapeutic discoveries, with an upfront payment of $17.5 million and potential milestone payments of up to $440 million.
The collaboration will focus on developing antisense oligonucleotides for neuro and kidney diseases, with CAMP4 eligible to receive up to $440 million in development and commercial milestone payments.
CAMP4 has also announced the pricing of a $30.0 million underwritten offering of common stock, providing additional funding for the company's RNA-based therapeutic research and development efforts.

Generated by AI

Community

Of the messages about CAMP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	6.19%
Newcomers	—	—	100%	93.81%

Regulars· Oct 6

CalAmp's Q2 revenue fell 15% to $61.7M, missing consensus estimates of $70.4M, and the company's shares slid 8.8% as a result.
Analyst Scott Searle of ROTHMKM downgraded CalAmp's price target from $6 to $5, citing a decrease in potential upside.
CalAmp's Q2 earnings were break-even, with the company's shares down about 90% this year.

Newcomers· Mar 10

$CAMP surges 49.40% on certification process completion, with upcoming investor conferences drawing significant attention.
The company's upcoming investor conferences signal strategic outreach, with news supporting visibility but the magnitude of the move suggesting deeper positioning.
Operating leverage expansion and key levels being tested are catalysts for the move, with investor conference participation supporting the news, but caution is required due to high volatility.

Generated by AI

Camp4 Therapeutics

Social

Mar 10

Bullish· Mar 10

Bearish· Sep 10

Earnings· Sep 26

Announcements· Dec 18

Regulars· Oct 6

Newcomers· Mar 10

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow (NASDAQ:CAMP) 2026-09-28

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 receives UK authorization for SYNGAP1 trial of CMP-002

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Camp4 Therapeutics at Cantor conference: pushing first SYNGAP1 trial

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

Also Discussed

Camp4 Therapeutics Corporation

Company Information

Location

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow (NASDAQ:CAMP) 2026-09-28

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 receives UK authorization for SYNGAP1 trial of CMP-002

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Camp4 Therapeutics at Cantor conference: pushing first SYNGAP1 trial

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

Also Discussed

Social

Mar 10

Bullish· Mar 10

Bearish· Sep 10

Earnings· Sep 26

Announcements· Dec 18

Regulars· Oct 6

Newcomers· Mar 10